Laura Prieto García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Prieto García has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anna Torrent
Hematology Department, ICO Badalona. Hospital Universitari Germans Trias i Pujol, Badalona, Spain
1 shared publication - António Campos
Marrow Transplant Department Instituto Português de Oncologia Porto Portugal
1 shared publication - Beatriz Aguado
Hematology Department Hospital Universitario La Princesa Madrid Spain
1 shared publication - Carlos Pinho
Departamento de Cirurgia Plástica e Reconstrutiva, Instituto Português de Oncologia do Porto FG, Porto, Portugal
1 shared publication - Christelle Ferra
Institut Català d'Oncologia - Badalona. H. Germans Trias i Pujol
1 shared publication - Dolores Caballero Barrigón
Hematology Department, Hospital Universitario de Salamanca IBSAL (Instituto Biosanitario de Salamanca) Salamanca Spain
1 shared publication
Latest Publications
- 18 March 2023
- Published by Wiley in European Journal of Haematology
- Vol. 110 (6) , 659-668
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation
The outcomes of patients with acute lymphoblastic leukaemia (ALL) presenting relapse after allogeneic stem cell transplant (allo‐SCT) are poor, with few data available in this setting.Objective and Methods: To evaluate the outcomes of patients with ALL presenting relapsed after allo‐SCT, we performed a retrospective study including 132 from 11 centres in Spain.Results: Therapeutic strategies consisted of palliative treatment (n = 22), chemotherapy (n = 82), tyrosine kinase inhibitors (n = 26), immunotherapy with inotuzumab and/or blinatumumab (n = 19), donor lymphocyte infusions (n = 29 pts), second allo‐SCT (n = 37) and CAR T therapy (n = 14). The probability of overall survival (OS) at 1 and 5 years after relapse was 44% (95% confidence interval [CI]: 36%; 52%) and 19% (95% CI: 11%; 27%). In the 37 patients undergoing a second allo‐SCT, the 5‐year estimated OS probability was 40% [22%; 58%]. Younger age, recent allo‐SCT, late relapse, 1st complete remission at 1st allo‐SCT and chronic graft‐versus‐host disease confirmed their positive impact on survival in the multivariable analysis.Conclusion: Despite the poor prognosis of patients with ALL presenting relapse after a first allo‐SCT, some can be satisfactorily rescued and a second allo‐SCT still remains a valid option for selected patients. Moreover, emerging therapies really might improve ALL patients outcome when relapsing after an allo‐SCT.
- 18 March 2023
- Published by Wiley in European Journal of Haematology
- Vol. 110 (6) , 659-668
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation
The outcomes of patients with acute lymphoblastic leukaemia (ALL) presenting relapse after allogeneic stem cell transplant (allo‐SCT) are poor, with few data available in this setting.Objective and Methods: To evaluate the outcomes of patients with ALL presenting relapsed after allo‐SCT, we performed a retrospective study including 132 from 11 centres in Spain.Results: Therapeutic strategies consisted of palliative treatment (n = 22), chemotherapy (n = 82), tyrosine kinase inhibitors (n = 26), immunotherapy with inotuzumab and/or blinatumumab (n = 19), donor lymphocyte infusions (n = 29 pts), second allo‐SCT (n = 37) and CAR T therapy (n = 14). The probability of overall survival (OS) at 1 and 5 years after relapse was 44% (95% confidence interval [CI]: 36%; 52%) and 19% (95% CI: 11%; 27%). In the 37 patients undergoing a second allo‐SCT, the 5‐year estimated OS probability was 40% [22%; 58%]. Younger age, recent allo‐SCT, late relapse, 1st complete remission at 1st allo‐SCT and chronic graft‐versus‐host disease confirmed their positive impact on survival in the multivariable analysis.Conclusion: Despite the poor prognosis of patients with ALL presenting relapse after a first allo‐SCT, some can be satisfactorily rescued and a second allo‐SCT still remains a valid option for selected patients. Moreover, emerging therapies really might improve ALL patients outcome when relapsing after an allo‐SCT.